GSA Capital Partners LLP Makes New Investment in Quanterix Corporation $QTRX

Key Points

• GSA Capital Partners acquired 410,252 Quanterix shares worth approximately $1.77 million, representing about 0.87% of the company. Institutional investors collectively own 86.48% of QTRX.
• Quanterix reported a quarterly loss of $1.04 per share, substantially missing the $0.41 consensus estimate, while revenue of $32.91 million fell short of the $37.48 million forecast.
• QTRX opened at $2.59, near its 12-month low, as analysts maintained a cautious outlook. The stock carries an average “Reduce” rating and a $3.50 consensus price target.

GSA Capital Partners LLP bought a new stake in Quanterix Corporation (NASDAQ:QTRX - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 410,252 shares of the company's stock, valued at approximately $1,772,000. GSA Capital Partners LLP owned approximately 0.87% of Quanterix as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in QTRX. Farther Finance Advisors LLC acquired a new stake in shares of Quanterix during the fourth quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in Quanterix in the fourth quarter valued at $27,000. Quarry LP raised its holdings in Quanterix by 277,300.0% in the third quarter. Quarry LP now owns 5,548 shares of the company's stock valued at $30,000 after acquiring an additional 5,546 shares in the last quarter. AXQ Capital LP acquired a new position in Quanterix during the 4th quarter worth $70,000. Finally, Renaissance Technologies LLC acquired a new position in Quanterix during the 4th quarter worth $75,000. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Price Performance

Quanterix stock opened at $2.59 on Monday. Quanterix Corporation has a 12 month low of $2.15 and a 12 month high of $8.77. The company has a fifty day moving average price of $3.62 and a two-hundred day moving average price of $4.06. The company has a market cap of $122.48 million, a PE ratio of -0.98 and a beta of 1.07.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.63). Quanterix had a negative return on equity of 26.09% and a negative net margin of 80.25%.The business had revenue of $32.91 million for the quarter, compared to analyst estimates of $37.48 million.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group dropped their target price on shares of Quanterix from $8.00 to $4.00 and set a "hold" rating for the company in a research report on Monday, April 20th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Quanterix in a research report on Friday, August 7th. TD Cowen decreased their price target on Quanterix from $4.00 to $3.00 and set a "hold" rating for the company in a research note on Tuesday, August 11th. Finally, Wall Street Zen lowered Quanterix from a "hold" rating to a "sell" rating in a report on Saturday. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Reduce" and an average price target of $3.50.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Corporation (NASDAQ:QTRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source